Underwriting Focus 2018, No. 2
Issue: November 2018 |
By Dr. John O'Brien, Life/Health Chief Medical Officer, London
Dr. Sara Kannampuzha, Life/Health Associate Underwriter, Cologne
Annika Tiedemann, Life/Health Underwriting Manager, Cologne
Assoc. Prof. Dr. Rupert Bartsch, Medical University of Vienna, Austria
Rime Bictache-Weiler, Underwriter, Cologne
Jon Parker, Senior Underwriting Specialist, London
“Genetics” is a globally growing topic – not only in medicine but also in insurance. Genetic testing allows individual disease management with the help of personalised medicine and a more accurate risk assessment when deciding about future disease developments. A genetic test can reveal that an otherwise healthy person has a higher predisposition to develop a specific disease. This information has the potential to affect insurance decisions by both the insurers and their customers.
In many markets the use of genetic information in insurance is restricted or forbidden by law. Whether disclosed test results can be used during the underwriting process depends on many factors such as sum assured, predictivity of the test or benefit for the client.
In this current edition of Underwriting Focus please read about the power of genetic testing, worldwide regulations and advances in personalised medicine. Additionally we discuss two specific genetic diseases – breast cancer and cystic fibrosis – and their assessment in underwriting.